As the understanding of SIRT1 activity and NAD+ metabolism in renal physiology increases, many different pharmacological approaches are being developed to maintain SIRT1 activity and increase NAD+ production in age- and metabolism-related disorders, with the purpose of ameliorating kidney injury in animal models of renal diseases. This evidence concerns the gene SIRT1 and kidney disorder.